ABVD与 escalated BEACOPP 方案治疗晚期霍奇金淋巴瘤:一项欧洲多中心研究结果
该回顾性研究纳入2009年10月至2018年10月欧洲7个癌症中心(奥地利2个、意大利5个)397例晚期霍奇金淋巴瘤患者,比较ABVD与BEACOPPesc方案。BEACOPPesc组PET完全代谢缓解率更高(85% vs 76%,p=.01)且缓解后复发率更低(9% vs 16.6%,p=.043),但严重不良事件更常见;两组总生存相似(p=.94),总体无进展生存无统计学差异(p=.11)。
要点
- BEACOPPesc组PET完全代谢缓解率85%,ABVD组76%(p=.01)。
- 中位随访8年,BEACOPPesc组缓解后复发9%,ABVD组16.6%(p=.043)。
- 两组总生存相似(p=.94),总体无进展生存无统计学差异(p=.11)。
核心结论
- ABVD是晚期霍奇金淋巴瘤有效且毒性较低的治疗选择;BEACOPP虽初始肿瘤控制更好,但两方案长期结局相似。
研究设计与样本
- 回顾性分析,2009年10月至2018年10月在7个欧洲癌症中心(奥地利2个、意大利5个)评估397例接受ABVD或BEACOPPesc治疗的晚期霍奇金淋巴瘤患者。
主要发现
- PET完全代谢缓解率:ABVD组76% vs BEACOPPesc组85%(p=.01)。
- 严重不良事件BEACOPPesc组比ABVD组更常见。
- 中位随访8年,达到完全代谢缓解后复发:BEACOPPesc组9% vs ABVD组16.6%(p=.043)。
- 总体无进展生存两组无统计学差异(p=.11),高危患者接受BEACOPPesc治疗有更优无进展生存的趋势(p=.074)。
- 总生存两组相似(p=.94)。
临床怎么用
- 原文结论认为ABVD是晚期霍奇金淋巴瘤有效且毒性较低的治疗选择;BEACOPP虽初始肿瘤控制更好,但长期结局相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The optimal first-line treatment for advanced-stage Hodgkin's lymphoma (HL) is still a matter of debate. While ABVD is less toxic and as effective as other, more intensive chemotherapy regimens, escalated BEACOPP (BEACOPPesc) is superior to ABVD for initial disease control and prolonged time-to-relapse. However, this advantage is associated with higher rate of early and late toxicities. As most of these data have been accumulated from clinical trials, a retrospective analysis was conducted in a large database of patients treated outside clinical trials to investigate the advantages and disadvantages of these regimes in a real-world setting. From October 2009 to October 2018, 397 advanced-stage HL patients treated with either ABVD or BEACOPPesc were retrospectively assessed in 7 European cancer centers (2 Austrian and 5 Italian centers). Complete metabolic remission (CMR) by PET was achieved in 76% and 85% of patients in the ABVD and BEACOPPesc groups, respectively (p = .01). Severe adverse events occurred more frequently with BEACOPPesc than ABVD. At a median follow-up of 8 years, 9% of the patients who achieved CMR after BEACOPPesc relapsed compared to 16.6% in the ABVD group (p = .043). No statistical difference in progression free survival (PFS) was observed between the two cohorts overall (p = .11), but there was a trend towards a superior PFS in high-risk patients treated with BEACOPPesc (p = .074). Nevertheless, overall survival was similar between the two groups (p = .94). In conclusion, we confirm that ABVD is an effective and less toxic therapeutic option for advanced-stage HL. Although BEACOPP results in better initial tumor control, the long-term outcome remains similar between the two regimens.
引用
- Mondello P, Musolino C, Dogliotti I, et al. ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study. Am J Hematol. 2020. PMID: 32419224. doi:10.1002/ajh.25871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。